Custom pharmaceutical-grade polymers and lipids are supplied as route-adaptable API platforms for tablet, capsule, granule, oral liquid, and injectable dosage manufacturing. The product line operates under ICH Q7 GMP and is supported by batch documentation aligned to 21 CFR 210 and 21 CFR 211. Synthetic polymers span weight-average molecular weight from 2.0×10³ Da to 2.5×10⁵ Da; oral grades are released with polydispersity index ≤1.8, while injectable grades are controlled to ≤1.4. Lipid APIs range from 600 Da to 3.5×10³ Da, with total organic impurities controlled by HPLC-CAD to total impurities ≤0.50% w/w and unspecified individual impurities ≤0.10% w/w. Residual monomers are limited to ≤0.10% w/w for polymer products, and residual solvent profiles are controlled to ICH Q3C Option 1 via headspace gas chromatography according to USP <467>. Injectable grades carry bacterial endotoxin release limits ≤0.25 EU/mg, bioburden ≤10 CFU/g, and subvisible particulate data generated after dissolution or reconstitution at 1.0% w/v using light obscuration per USP <787> and USP <788>. Base model designations are POLY-1000 through POLY-5000 for synthetic polymers and LIPID-2000 through LIPID-7000 for defined lipids; a hyphenated suffix encodes molecular weight band, counterion or lipid headgroup, and lyophilization compatibility. The materials are supplied in nitrogen-flushed sealed aluminium pouches or Type I glass vials, with certificates of analysis, residual solvent reports, and stability protocols.

What Differentiates a Pharma-Grade Custom Polymer from a Technical-Grade Feedstock?

The difference is not compositional identity alone; it is the removal of catalyst fragments, oligomeric tails, and process-related impurities to levels acceptable for parenteral and oral drug product risk profiles. Technical-grade feedstocks of the same monomer composition frequently carry residual tin or palladium from polymerization, uncontrolled low-molecular-weight fractions, and peroxide-forming impurities that are not specified for pharmaceutical use. Custom pharmaceutical grades are purified by sequential precipitation or tangential flow filtration, and the resulting batch is tested by SEC-MALS in accordance with ISO 16014-2 to confirm both Mn and Mw; the target polydispersity index is a controlled specification, not an observed range. Residual metal content is measured by ICP-MS per USP <233> and evaluated against ICH Q3D Option 1 oral and parenteral permitted daily exposure limits. For injectable lipid APIs, the distinguishing impurity profile includes peroxide value ≤2.0 meq O₂/kg, p-anisidine value ≤10.0 per AOCS Cd 18-90, and free fatty acid ≤0.5% w/w. These release limits are supported by a Type II drug master file or equivalent regulatory dossier, allowing the drug product applicant to reference the quality data without re-characterizing the raw material from first principles.

For oral tablet and capsule formulations, the custom polymer may be used as a matrix-forming API or as a functional carrier with controlled release behavior. The critical processing difference from generic technical polymers is the absence of low-molecular-weight impurities that plasticize the tablet matrix and reduce the glass transition temperature. Production-scale batches have shown that reducing oligomer content below 0.3% w/w stabilizes tablet hardness and dissolution after 75°C open-pan drying. Where published data for a specific monomer combination is limited, process qualification is performed by design of experiments using the intended rotary press and fluid-bed dryer.

For injectable lipid APIs, residual solvent removal is performed in a thin-film evaporator at 50–65°C and ≤10 mbar absolute pressure; residence time is held below 45 min to suppress transesterification byproducts. Headspace GC per USP <467> confirms methylene chloride below 600 ppm and methanol below 3000 ppm, but if a batch exceeds ICH Q3C Option 1 limits the material is reworked under vacuum and reanalyzed rather than released by averaging. Oxidative stability is monitored by peroxide value per Ph Eur 2.5.5, with injectable lipid release limits ≤2.0 meq O₂/kg and oral lipid limits ≤5.0 meq O₂/kg; p-anisidine value is ≤10.0 per AOCS Cd 18-90. Storage under nitrogen at −20±5°C with desiccant limits peroxide drift to 0.5 meq O₂/kg over 24 months in ongoing stability protocols. Lipid batches containing unsaturated fatty acid chains are incompatible with oxygen headspace above 1.0% v/v during hold steps; any container opened outside a nitrogen-purged isolator is assigned a 48 h use window.

Granulation and Compression Boundaries Are Defined by Moisture and Glass Transition

Oral-grade polymer APIs are characterized by laser diffraction particle size analysis per USP <429> and ISO 13320-1:2020; routine release includes D10, D50, and D90, with tight control over the <75 µm fines fraction because excess fines increase granulation liquid demand and produce harder granules after drying. Bulk and tapped density are determined per USP <616>; powder flow is classified by USP <1174> using a Flodex or shear cell method. Polymers with glass transition temperatures below 30°C are cryogenically milled at −40°C under nitrogen to avoid screen blinding; the same material processed under ambient conditions on an impact mill can form a fused layer on the rotor within 15 min of continuous operation.

High-shear wet granulation is performed on a 200 L vertical granulator with impeller tip speed 6–12 m/s and chopper speed 1500 rpm; granulation liquid is added at 2–4% w/w/min until endpoint torque reaches 70–85% of the motor load observed with the dry powder. Drying in a fluid-bed dryer at inlet air 60–75°C to loss on drying ≤1.0% w/w avoids glass transition-related agglomeration. Tablet compression on a rotary press at 10–25 kN and dwell time 10–30 ms is typical; ejection force above 500 N may indicate insufficient lubrication or residual moisture, and the batch is reconditioned rather than accepted by adding additional lubricant. Capsule filling performance is evaluated with a tamping pin or dosator machine at minimum 25,000 capsules/h; the formulation is acceptable when weight variation remains within ±5.0% of target and no capsule deformation is observed. At ambient relative humidity above 60%, oral-grade polymers require pre-drying in a vacuum oven at 40°C for 4 h before weighing for direct compression, because hygroscopic grades gain more than 2.0% w/w moisture within 8 h.

Injectable Route Critical Thresholds for Endotoxin and Subvisible Particulate

Injectable-grade polymer and lipid APIs are released with bacterial endotoxin limits per USP <85>; for high-risk parenteral applications the release limit is ≤0.25 EU/mg, and for lipid nanoparticle components it is tightened to ≤0.10 EU/mg. Sterility testing is not routinely used for release of the API unless the customer orders a sterile-filled configuration; when sterile API is ordered, the material is filled under ISO 14644-1 Class 5 conditions and tested according to USP <71> with 14-day incubation. Subvisible particulate matter is measured by light obscuration per USP <788> after reconstitution at 1.0% w/v; the release limit is ≤6000 particles/container at ≥10 µm and ≤600 particles/container at ≥25 µm. Visible particulates are assessed per USP <790> and must be absent.

pH and osmolality are not intrinsic polymer properties but are critical when the custom polymer is formulated as an injectable solution. A 1.0% w/v aqueous solution of POLY-3000 in water for injection has a typical pH 6.2–7.0; osmolality is measured by freezing point depression per USP <785> and is adjusted with sodium chloride or mannitol to 280–320 mOsm/kg for isotonic administration. Cationic polymer grades are incompatible with anionic surfactants such as sodium dodecyl sulfate because ionic complexation produces an insoluble precipitate within 5 min at room temperature in 100 mM phosphate buffer; this operational boundary must be included in the compatibility protocol. Amine-containing additives should be avoided with reactive carbonyl lipids due to Schiff base formation and accelerated discolouration, which is a known incompatibility. Published data for this specific polymer–lipid combination in high-pressure microfluidization is limited; process qualification therefore uses a worst-case formulation design of experiments at 10,000–20,000 psi and 3–5 passes to define the operating window.

For dual-route polymers that are lyophilized, reconstitution time is a critical in-use property. The freeze-dried cake is produced by freezing at −45°C for 240 min, primary drying at −20°C and 0.15 mbar for 48 h, and secondary drying at 25°C for 12 h. Cake collapse occurs if the product temperature exceeds the collapse temperature during primary drying; for amorphous polymer grades the collapse temperature is typically −25°C to −18°C. The reconstituted solution is filtered through a 0.2 µm polyethersulfone membrane, and the filtration time is recorded; an increase of more than 40% compared with the qualification batch indicates aggregation or particulate contamination. These parameters are included in the technical dossier because they define the operational boundary between acceptable parenteral use and subvisible particulate failure.

When a Single Polymer Backbone Must Meet Oral and Injectable Specifications

Customers occasionally request one polymer backbone for both oral tablet and injectable dosage forms to harmonize regulatory filings. In that case, the specification defaults to the most restrictive route: bacterial endotoxin ≤0.25 EU/mg, bioburden ≤10 CFU/g, residual solvent Class 2 sum ≤0.10% w/w, and subvisible particulate matter by USP <788> after reconstitution. The dual-route grade is produced by post-polymerization purification using ultrafiltration-diafiltration with a 10 kDa nominal molecular weight cut-off membrane; this removes low-molecular-weight oligomers and reduces polydispersity index from 1.8 to 1.3 in production campaigns. The resulting material is lyophilized to ≤0.5% w/w residual water and packed in single-use Type I glass vials under nitrogen. The same backbone may be used in tablet direct compression only if the glass transition temperature is above 45°C; below this threshold, the material must be granulated or adsorbed onto a carrier to prevent sticking to punch faces. This route convergence is a key difference from suppliers offering only fixed oral or fixed injectable grades, because the custom specification is generated from the drug product’s quality target product profile rather than from a predefined catalogue monograph.